Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Breast cancer drug's skin side effects under the microscope

NCT ID NCT06401889

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times

Summary

This study looks at how aromatase inhibitor therapy changes skin quality and self-esteem in breast cancer survivors. Researchers will use skin imaging and surveys to track changes in 35 women starting this hormone therapy. The goal is to better understand and manage these side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224-9980, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors understand and manage skin changes in breast cancer survivors, potentially improving quality of life.

What could go wrong

This is a small, observational study with only 35 participants. It does not test a treatment, so it may not lead to direct improvements.

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma in situ estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.